Developing new mouse models for pediatric acute myeloid leukemia
Cross-species development and credentialing of pediatric AML models
['FUNDING_R01'] · WASHINGTON UNIVERSITY · NIH-10999385
This study is working to create new mouse models that mimic the different types of high-risk acute myeloid leukemia in children, so researchers can better understand the disease and find more effective treatments for young patients.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WASHINGTON UNIVERSITY (nih funded) |
| Locations | 1 site (SAINT LOUIS, UNITED STATES) |
| Trial ID | NIH-10999385 on ClinicalTrials.gov |
What this research studies
This research aims to create and validate new mouse models that accurately represent high-risk pediatric acute myeloid leukemia (AML). By utilizing patient data, the study will focus on the genetic diversity of AML, which includes various molecular subtypes that are often overlooked in current models. The goal is to better understand these subtypes and develop targeted therapies that can improve treatment outcomes for children suffering from this aggressive cancer. The research will involve collaboration among multiple experts to ensure a comprehensive approach to model development.
Who could benefit from this research
Good fit: Ideal candidates for this research are children diagnosed with high-risk acute myeloid leukemia, particularly those with rare molecular subtypes.
Not a fit: Patients with low-risk or non-acute forms of leukemia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment options for children with high-risk pediatric AML.
How similar studies have performed: While there have been advancements in cancer modeling, this approach to developing models specifically for high-risk pediatric AML is relatively novel and has not been extensively tested.
Where this research is happening
SAINT LOUIS, UNITED STATES
- WASHINGTON UNIVERSITY — SAINT LOUIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MAGEE, JEFFREY ALAN — WASHINGTON UNIVERSITY
- Study coordinator: MAGEE, JEFFREY ALAN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.